BPC-157 vs GHK-Cu — Healing & Tissue Repair Peptide Comparison
BPC-157 and GHK-Cu are both studied for tissue repair through different mechanisms. No head-to-head trial of the two exists. This page reports what each compound is, which route each cited human study actually tested, and the evidence level for each.
On this page
Molecule Identity
BPC-157 is a synthetic 15-amino-acid peptide based on a protective protein found in gastric juice. GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine plus a copper ion), first isolated by Loren Pickart in 1973 from human plasma; it also occurs in saliva and urine, with plasma levels declining with age.
| BPC-157 | GHK-Cu | |
|---|---|---|
| What it is | 15-amino-acid synthetic peptide, derived from a protein in human gastric juice | Copper-binding tripeptide (Glycine-Histidine-Lysine + Cu2+), naturally occurring in human plasma, saliva, and urine |
| Proposed mechanism | Angiogenesis (VEGF/eNOS), EGR-1-mediated growth factor signaling, FAK-paxillin pathway | Copper-shuttling into cells (lysyl oxidase, superoxide dismutase cofactor); modulates expression of thousands of genes tied to collagen synthesis and tissue remodeling |
| Route tested in the cited human study | Intra-articular injection (into the knee joint) | Topical (facial serum) |
| Human evidence | Lee & Padgett 2021 (PMID 34324435) — retrospective case series, intra-articular knee injection | Badenhorst et al. 2016 (DOI 10.4172/2329-8847.1000166) — randomized, double-blind, split-face trial, topical only |
| Injectable/subcutaneous human evidence | None identified | None identified — every human study located for GHK-Cu tested it topically |
| Evidence level | Human Observational | Human RCT (topical use only) |
The two cited human studies used different routes of administration (intra-articular injection vs topical serum) in different populations. Neither generalizes to the other compound's route or to subcutaneous/injectable use more broadly.
Human Evidence, by Molecule
BPC-157's human evidence is Lee & Padgett 2021 (Altern Ther Health Med, PMID 34324435), a retrospective chart review of 17 patients who received an intra-articular knee injection of BPC-157 at 4 mg. This is Human Observational evidence — a retrospective, uncontrolled case series, not a randomized trial — and its route (intra-articular) is specific to that study.
GHK-Cu's human evidence is topical in every study located. Badenhorst et al. 2016 (J Aging Sci, DOI 10.4172/2329-8847.1000166) is a randomized, double-blind, split-face trial applying a 0.1%-equivalent nano-lipid-carrier GHK-Cu serum to the faces of 40 women (ages 40–65) once daily for 8 weeks, reporting a 31.6% reduction in wrinkle volume versus a Matrixyl 3000 comparator and a 55.8% reduction versus a vehicle-only control. A currently recruiting Phase 2 trial (NCT07437586, planned N=60) is testing a 0.1% w/w topical GHK-Cu gel on standardized wounds but has not yet posted results. No human study of injected or subcutaneous GHK-Cu was identified.
Animal Evidence
BPC-157's animal evidence includes Biçer et al. 2026 (PMID 42542926), a rat Achilles-tendon-transection model, and Japjec et al. 2021 (PMID 34829776), a rat myotendinous-junction model — both dosed by body weight (µg/kg or ng/kg), intraperitoneally or perorally, not subcutaneously.
GHK-Cu's animal evidence includes rat ischemic skin-flap models showing reduced wound size versus control, and systemic-activity studies in rats, mice, and pigs where GHK-Cu injected in one tissue area was reported to affect healing at distant sites — the basis for injectable-route interest, though no human trial has tested that route.
Adverse events reported in the cited studies
Lee & Padgett 2021 reported no serious adverse events in its 17-patient BPC-157 case series. Badenhorst et al. 2016 did not report treatment-related adverse events in its topical GHK-Cu trial; Prof. Peptide has not identified a published adverse-event table for injectable GHK-Cu, since no human injectable trial was located.
Evidence Level
BPC-157: Human Observational (Lee & Padgett 2021, PMID 34324435 — intra-articular knee injection). GHK-Cu: Human RCT for topical use only (Badenhorst et al. 2016, DOI 10.4172/2329-8847.1000166) — no human trial of injectable GHK-Cu exists. Full profiles, including each compound's wider citation list, are on the BPC-157 and GHK-Cu profile pages.
FAQ
Does either compound have human evidence for injectable/subcutaneous use?
BPC-157's one identified human study, Lee & Padgett 2021 (PMID 34324435), used intra-articular injection (into the knee joint), not subcutaneous. No human study of injected GHK-Cu was identified for this page — every GHK-Cu human study located tested it topically. Neither compound has published human evidence for the subcutaneous route that community protocols commonly describe.
Is there a human trial of GHK-Cu for corneal healing?
No corneal-healing human trial of GHK-Cu was identified in the sources checked for this page. The human evidence located is Badenhorst et al. 2016, a topical facial-wrinkle trial, and a currently recruiting Phase 2 topical wound-gel trial (NCT07437586) that has not yet posted results. A claim of a completed GHK-Cu corneal trial should not be treated as established without a citation.
Are BPC-157 and GHK-Cu ever studied in the same trial?
No head-to-head or combination human trial of BPC-157 and GHK-Cu was identified. Any comparison between the two draws on separate studies, in different populations, using different routes of administration.
What is GHK-Cu's regulatory status compared to BPC-157?
Topical GHK-Cu is sold in cosmetic formulations without FDA drug approval, under FDA's cosmetics framework rather than its drug framework. Injectable GHK-Cu is not FDA-approved; on FDA’s compounding lists (current as of April 22, 2026), injectable GHK-Cu, previously in Category 2, is on FDA’s list of substances “nominated but withdrawn”, and non-injectable GHK-Cu sits in 503A Category 1 (under evaluation, not approved). BPC-157 is not FDA-approved; FDA lists it among bulk drug substances “nominated but withdrawn” — previously in Category 2, now in neither Category 2 nor Category 1 (FDA page current as of April 22, 2026); neither status authorizes compounding.
References
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. https://pubmed.ncbi.nlm.nih.gov/42542926/
- Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. J Aging Sci. 2016;4:166. DOI 10.4172/2329-8847.1000166. https://doi.org/10.4172/2329-8847.1000166
- Topical GHK-Cu Gel for Acute Skin Wound Healing, NCT07437586. https://clinicaltrials.gov/study/NCT07437586
Have a question about BPC-157 vs GHK-Cu — Evidence, Mechanism, and Route Differences? Send us an email